Sprycel

Type: Product

Name: Sprycel

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Global Sprycel market: Latest market research analysed - We have released our new PharmaPoint Drug Evaluation report, "". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion ... [Published companiesandmarkets.com - May 22 2013]

Entities: Sprycel, chronic myeloid leukemia, market analysis, Kinase

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Gleevec

CML Drug Revenue in Japan to Grow, Despite Global Decline

- Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient population will ensure steady growth of Japan's Chronic Myeloid Leukemia (CML) market over the next decade, forecasts a new report from research ... [Published PharmiWeb - May 20 2013]

Entities: chronic myeloid leukemia, Sprycel, Japan, Gleevec

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Tackling Cancer: Leukemia's Biggest Current and Upcoming Players

It's a 100% FREE Motley Fool service...As I noted 11 weeks ago, cancer statistics are both staggering and disappointing. Although cancer deaths per 100,000 people have been on the downswing since 1991 thanks to access to more effective medications and ... [Published Motley Fool Discussion Boards - May 19 2013]

Entities: Acute Lymphoblastic Leukemia, Leukaemia, chronic myeloid leukemia

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Cancer Treatments "Unaffordable", and Will Drive Rapid Transition to Generics and Market Decline, Says

• Chronic myeloid leukaemia (CML) branded therapies market to decline by $900 million in 10 years in the seven major markets• Unsustainable CML drug prices a major barrier to market growth• Cost constraints will limit the use of new market entrants and ... [Published BioSpace - May 14 2013]

Entities: chronic myeloid leukemia, Oncology, Drugs

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Cancer Treatments ‘Unaffordable’ and Will Drive Rapid Transition to Generics and Market Decline, Says GlobalData

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and healthcare systems that does not necessarily correlate with the survival benefit the drug provides, and which is driving the rapid transition to generics ... [Published Pharma-Mag - May 09 2013]

Entities: chronic myeloid leukemia, Drugs, Cancer, Oncology

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Bristol-Myers Squibb's Management Discusses Q1 2013 Results - Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q1 2013 Earnings Conference Call April 25, 2013 10:30 AM ETOperatorGood day and welcome to today’s First Quarter Earnings 2013 Release Conference Call. This call is being recorded. At this time, I would like to turn ... [Published Seeking Alpha - Apr 26 2013]

Entities: John Elicker, ELIQUIS, Abatacept, Bristol-Myers Squibb Company, Onglyza

First reported Apr 25 2013 - Updated Apr 25 2013 - 2 reports

Bristol-Myers Squibb Company

Bristol net plunges 45 pct. on generic competition

Drugmaker Bristol-Myers Squibb Co. on Thursday posted a 45 percent drop in first-quarter profit as reduced spending and a sharply lower tax rate couldn't make up for plunging sales from increased generic competition to blood thinner Plavix.Revenue from ... [Published Equities.com - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Avalide, Plavix

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Bristol-Myers Squibb Profit Plunges On Patent Expiries Of Cardiovascular Drugs

Biopharmaceutical company Bristol-Myers Squibb Co. (BMY: Quote) Thursday reported a plunge in profit for the first quarter, as sales dropped 27 percent after U.S. patents expired last year for blood pressure drug Avapro/Avalide and anti clotting medication ... [Published RTTNews.com - Apr 25 2013]

Entities: Avalide, Bristol-Myers Squibb Company, Avapro

First reported Apr 05 2013 - Updated Apr 05 2013 - 1 reports

4 Healthcare Stock Stories for Weekend Investment Wellness

Johnson & Johnson ( NYSE:JNJ ): Current price $81.82 The United States Court of Appeals for the Federal Circuit has reversed a Texas jury , ruling that the company’s subsidiary Cordis Corp. did not infringe on a patent owned by a radiologist in making ... [Published Wall St. Cheat Sheet - Apr 05 2013]

Entities: Priligy, Cordis Corp, BOSULIF, Furiex Pharmaceuticals, Menarini Group

First reported Jan 23 2013 - Updated Jan 24 2013 - 1 reports

Plavix Patent Cliff Will Impact Bristol-Myers Earnings

By Trefis : Bristol-Myers Squibb ( BMY ) will announce fourth quarter and full year 2012 earnings Thursday, January 24. The biopharmaceutical major is coming off a patent cliff. In May 2012 it lost patent exclusivity of its blockbuster cardiovascular ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 23 2013]

Entities: Plavix, Bristol-Myers Squibb Company, Patent

First reported Nov 29 2012 - Updated Nov 30 2012 - 1 reports

Human medicines European Public Assessment Report (EPAR): Sprycel, dasatinib, Revision: 19, Authorised

[Published Pending EC decisions and European Public Assess ... - Nov 29 2012]

Entities: Sprycel, Dasatinib

Quotes

"When I see something that I like, when I am on the road, I simply pull over, stop and shoot" Lile said

Photographer David Bryan Lile sees magic in old buildings [Published Individual.com - 3 hours ago]

...And that could spur a major shift in the development timelines being provided by many drug developers. "A couple of years ago the big story was that immunotherapy can work" said Jedd Wolchok, director of immunotherapy at the Ludwig Center at Memorial Sloan-Kettering Cancer Center...

Bristol Myers Squibb And The New Wave Of Cancer Drugs [Published Seeking Alpha - May 20 2013]

But the study confirms that "it is possible to use modern genomic techniques to understand the pathophysiology of a disease – even a rare one – and by understanding the pathophysiology to perhaps be able to use available therapies to help patients today" Stone told MedPage Today

Genetic Search Yields Clues to Rare Cancers [Published MedPage Today - May 08 2013]

More Content

sort by: Date \| Relevance
Photographer David Bryan Lile sees magic in old... [Published Individual.com - 3 hours ago]
Japan Chronic Myeloid Leukemia Market Studied i... [Published Business Wire - May 23 2013]
Italy chronic myeloid leukemia market: Latest m... [Published TransWorldNews - May 23 2013]
Bosulif (Chronic Myeloid Leukemia) - Forecast a... [Published companiesandmarkets.com - May 22 2013]
Sprycel (Chronic Myeloid Leukemia) - Forecast a... [Published companiesandmarkets.com - May 22 2013]
Bristol-Myers Squibb's Management Presents at U... [Published Seeking Alpha - May 21 2013]
Bristol Myers Squibb And The New Wave Of Cancer... [Published Seeking Alpha - May 20 2013]
CML Drug Revenue in Japan to Grow, Despite Glob... [Published PharmiWeb - May 20 2013]
Tackling Cancer: Leukemia's Biggest Current and... [Published Motley Fool Discussion Boards - May 19 2013]
Cancer Treatments "Unaffordable", and Will Driv... [Published BioSpace - May 14 2013]
Cancer Treatments ‘Unaffordable’ and Will Drive... [Published Pharma-Mag - May 09 2013]
Cancer treatments are becoming unaffordable, sa... [Published Manufacturing Chemist - May 09 2013]
Genetic Search Yields Clues to Rare Cancers [Published MedPage Today - May 08 2013]
Bristol-Myers Has The Future Of Oncology Therapies [Published Seeking Alpha - May 05 2013]
Winning the War against Childhood Cancer [Published Daily Rx - Apr 29 2013]
Bristol-Myers Squibb's Management Discusses Q1 ... [Published Seeking Alpha - Apr 26 2013]
Bristol-Myers Reports In Line Earnings - Analys... [Published Zacks.com - Apr 25 2013]
UPDATE: Bristol-Myers Profit Drops 45% on Lower... [Published Capital.gr - Apr 25 2013]
Bristol net plunges 45 pct. on generic competition [Published Equities.com - Apr 25 2013]
Bristol-Myers Squibb Profit Plunges On Patent E... [Published RTTNews.com - Apr 25 2013]
Bristol profit drops sharply, but meets Wall St... [Published Sharenet - Apr 25 2013]
Bristol-Myers 1st-Quarter Net Drops 45% on Lowe... [Published Capital.gr - Apr 25 2013]
Brystol-Myers Squibbs Preview: Performance Of N... [Published Trefis - Apr 24 2013]
Patent loss pushes Lipitor to 17th rank in 2012... [Published PharmaBiz - Apr 08 2013]
4 Healthcare Stock Stories for Weekend Investme... [Published Wall St. Cheat Sheet - Apr 05 2013]
Orbitz Settles Dispute and 2 Stocks Reaching 52... [Published Wall St. Cheat Sheet - Apr 05 2013]
Indias rejection of cancer-drug patent could re... [Published Seattle Times - Apr 02 2013]
India's rejection of drug [Published WPRI - Apr 01 2013]
Research and Markets: Sprycel (Prostate Cancer)... [Published Business Wire Health News - Mar 12 2013]
New Research Report on Leukemia Therapeutics Ma... [Published PR.com Press Releases - Feb 22 2013]